We have partnered with Penn Medicine Lancaster General Health (LG Health) to launch a unique $300 million impact fund aimed at fast-tracking precision medicine technologies and practices that leverage AI and IoT to deliver affordable, individualized solutions at a massive scale.

Next page link icon
Previous page link icon

Aspire and LG Health are working together as Aspire
Ventures Precision Medicine Fund (AVP) General
Partners to realize the promise of precision medicine.

  • AVC
  • PennLGH
Learn More

How We Measure Our Impact

Traditional process vs. AVP’s process: With a repeatable
process and in-house accelerators, AVP drastically reduces the
time and capital required to get innovative products to market.

Process Red 10-15 years
Process green 5 years

An End-to-End Ecosystem for Accelerated Healthcare Innovation

Our fund’s unique structure equips ventures with an ecosystem of strategic partnerships and accelerators for each step of the venture development process — from ideation, to clinical trials, to FDA approval, to market adoption, to insurance reimbursement — maximizing our capital efficiency to rapidly advance new precision medicine technologies to market.


Aspire Ventures accelerates early-stage ventures with a support system of shared services, established processes, and proprietary technology components—such as our adaptive AI platform, A2I—that allows startups to focus on their unique value proposition from day one and reduce time and capital needed for ideation and R&D.


A2I, Aspire’s proprietary adaptive AI platform, uses AI to build and optimize new algorithms, dramatically reducing data science and technology resources needed to build AI-powered solutions. A2I exclusively powers the technology infrastructure of Aspire and its subsidiary companies.


LG Health, AVP fund co-GP, is a nationally recognized not-for-profit health system with over $1B in annual revenue and 350 employed specialty and primary-care physicians. LG Health will dedicate clinical experts and proprietary health system data to accelerate R&D, streamline clinical trials, and reduce time to secure FDA approval.


Smart Health Innovation Lab is a first-of-its-kind healthcare market adoption and insurance reimbursement accelerator built in collaboration by Aspire Ventures, Capital BlueCross, Clio Health, and LG Health. The lab validates and integrates market-ready healthcare technologies through a 12-week certification program.


Capital BlueCross (CBC) is an independent licensee of the BlueCross BlueShield Association, providing healthcare insurance to customers in 21 counties in Pennsylvania for 80 years. Through Smart Health Innovation Lab, CBC accelerates startups’ path to reimbursement with onsite payor experts and a commitment to test new reimbursement models.


Clio Health is an all-in-one health campus that reimagines the corporate self-insured model. Built from the ground up to natively support technologies like AI, IoT, and blockchain, Clio Health is a technologically savvy early adopter for AVP ventures, giving them a fast track to market.